Oren Livnat
Stock Analyst at HC Wainwright & Co.
(3.65)
# 751
Out of 4,893 analysts
140
Total ratings
45.14%
Success rate
7.8%
Average return
Main Sectors:
Top Industries:
Stocks Rated by Oren Livnat
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| PCRX Pacira BioSciences | Maintains: Buy | $48 → $65 | $23.17 | +180.54% | 20 | Apr 8, 2025 | |
| VRCA Verrica Pharmaceuticals | Reiterates: Neutral | n/a | $0.82 | - | 12 | Apr 8, 2025 | |
| COLL Collegium Pharmaceutical | Reiterates: Buy | $50 | $32.35 | +54.56% | 10 | Mar 24, 2025 | |
| TRVI Trevi Therapeutics | Reiterates: Buy | $13 | $6.17 | +102.59% | 7 | Mar 19, 2025 | |
| ANIP ANI Pharmaceuticals | Reiterates: Buy | $94 | $65.39 | +43.76% | 13 | Mar 17, 2025 | |
| ZVRA Zevra Therapeutics | Reiterates: Buy | $20 | $11.56 | +73.01% | 9 | Mar 13, 2025 | |
| JAZZ Jazz Pharmaceuticals | Maintains: Buy | $200 → $217 | $111.60 | +94.44% | 17 | Mar 10, 2025 | |
| XERS Xeris Biopharma Holdings | Reiterates: Buy | $6.6 → $8 | $5.34 | +49.81% | 11 | Mar 7, 2025 | |
| AVDL Avadel Pharmaceuticals | Reiterates: Buy | $21 | $9.55 | +119.90% | 16 | Mar 4, 2025 | |
| TARS Tarsus Pharmaceuticals | Reiterates: Buy | $73 | $41.25 | +76.97% | 9 | Feb 26, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Buy | $12 | $3.07 | +291.52% | 1 | Feb 18, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Buy | $7.5 | $3.82 | +96.34% | 6 | Jan 4, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $14 → $8 | $0.69 | +1,062.12% | 2 | May 13, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $43 → $60 | $3.21 | +1,755.49% | 5 | Aug 26, 2021 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $252 → $198 | $1.44 | +13,650.00% | 2 | May 7, 2021 |
Pacira BioSciences
Apr 8, 2025
Maintains: Buy
Price Target: $48 → $65
Current: $23.17
Upside: +180.54%
Verrica Pharmaceuticals
Apr 8, 2025
Reiterates: Neutral
Price Target: n/a
Current: $0.82
Upside: -
Collegium Pharmaceutical
Mar 24, 2025
Reiterates: Buy
Price Target: $50
Current: $32.35
Upside: +54.56%
Trevi Therapeutics
Mar 19, 2025
Reiterates: Buy
Price Target: $13
Current: $6.17
Upside: +102.59%
ANI Pharmaceuticals
Mar 17, 2025
Reiterates: Buy
Price Target: $94
Current: $65.39
Upside: +43.76%
Zevra Therapeutics
Mar 13, 2025
Reiterates: Buy
Price Target: $20
Current: $11.56
Upside: +73.01%
Jazz Pharmaceuticals
Mar 10, 2025
Maintains: Buy
Price Target: $200 → $217
Current: $111.60
Upside: +94.44%
Xeris Biopharma Holdings
Mar 7, 2025
Reiterates: Buy
Price Target: $6.6 → $8
Current: $5.34
Upside: +49.81%
Avadel Pharmaceuticals
Mar 4, 2025
Reiterates: Buy
Price Target: $21
Current: $9.55
Upside: +119.90%
Tarsus Pharmaceuticals
Feb 26, 2025
Reiterates: Buy
Price Target: $73
Current: $41.25
Upside: +76.97%
Feb 18, 2025
Reiterates: Buy
Price Target: $12
Current: $3.07
Upside: +291.52%
Jan 4, 2024
Reiterates: Buy
Price Target: $7.5
Current: $3.82
Upside: +96.34%
May 13, 2022
Maintains: Buy
Price Target: $14 → $8
Current: $0.69
Upside: +1,062.12%
Aug 26, 2021
Maintains: Buy
Price Target: $43 → $60
Current: $3.21
Upside: +1,755.49%
May 7, 2021
Maintains: Buy
Price Target: $252 → $198
Current: $1.44
Upside: +13,650.00%